These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20032229)

  • 1. Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms.
    Balsa A; Del Amo J; Blanco F; Caliz R; Silva L; Sanmarti R; Martínez FG; Tejedor D; Artieda M; Pascual-Salcedo D; Oreiro N; Collado MD; Andreu JL; Graell E; Simón L; Martínez A; Mulero J
    Rheumatology (Oxford); 2010 Mar; 49(3):458-66. PubMed ID: 20032229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygosity for DNASE2 single nucleotide polymorphisms in the 5'-regulatory region is associated with rheumatoid arthritis.
    Rossol M; Pierer M; Arnold S; Keysser G; Burkhardt H; Baerwald C; Wagner U
    Ann Rheum Dis; 2009 Sep; 68(9):1498-503. PubMed ID: 18812394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis.
    Kuriya B; Cheng CK; Chen HM; Bykerk VP
    Ann Rheum Dis; 2009 Sep; 68(9):1482-5. PubMed ID: 19015211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis.
    Poór G; Nagy ZB; Schmidt Z; Brózik M; Merétey K; Gergely P
    Ann N Y Acad Sci; 2007 Sep; 1110():23-32. PubMed ID: 17911417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study.
    Provan SA; Semb AG; Hisdal J; Stranden E; Agewall S; Dagfinrud H; Angel K; Atar D; Kvien TK
    Ann Rheum Dis; 2011 May; 70(5):812-7. PubMed ID: 21288959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of polymorphisms in interleukin-10 gene promoter with autoantibody production in patients with rheumatoid arthritis.
    Nemec P; Goldbergova MP; Gatterova J; Vasku A; Soucek M
    Ann N Y Acad Sci; 2009 Sep; 1173():501-8. PubMed ID: 19758192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6q23 polymorphisms in rheumatoid arthritis Spanish patients.
    Perdigones N; Lamas JR; Vigo AG; de la Concha EG; Jover JA; Urcelay E; Gutiérrez BF; Martínez A
    Rheumatology (Oxford); 2009 Jun; 48(6):618-21. PubMed ID: 19321514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
    Goëb V; Dieudé P; Daveau R; Thomas-L'otellier M; Jouen F; Hau F; Boumier P; Tron F; Gilbert D; Fardellone P; Cornélis F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mannose-binding lectin gene polymorphisms are associated with disease activity and physical disability in untreated, anti-cyclic citrullinated peptide-positive patients with early rheumatoid arthritis.
    Jacobsen S; Garred P; Madsen HO; Heegaard NH; Hetland ML; Stengaard-Pedersen K; Junker P; Lottenburger T; Ellingsen T; Smedegaard Andersen L; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Pødenphant J; Lindegaard H; Vestergaard A; Østergaard M; Hørslev-Petersen K
    J Rheumatol; 2009 Apr; 36(4):731-5. PubMed ID: 19273450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and genomic studies of PADI4 in rheumatoid arthritis.
    Harney SM; Meisel C; Sims AM; Woon PY; Wordsworth BP; Brown MA
    Rheumatology (Oxford); 2005 Jul; 44(7):869-72. PubMed ID: 15814578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis.
    Thabet MM; Huizinga TW; Marques RB; Stoeken-Rijsbergen G; Bakker AM; Kurreeman FA; White SJ; Toes RE; van der Helm-van Mil AH
    Ann Rheum Dis; 2009 Nov; 68(11):1775-80. PubMed ID: 19019892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.
    Kokkonen H; Johansson M; Innala L; Jidell E; Rantapää-Dahlqvist S
    Arthritis Res Ther; 2007; 9(3):R56. PubMed ID: 17553139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor.
    Radstake TR; Sweep FC; Welsing P; Franke B; Vermeulen SH; Geurts-Moespot A; Calandra T; Donn R; van Riel PL
    Arthritis Rheum; 2005 Oct; 52(10):3020-9. PubMed ID: 16200611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjögren's syndrome.
    van Noord C; Hooijkaas H; Dufour-van den Goorbergh BC; van Hagen PM; van Daele PL; van de Merwe JP
    Ann Rheum Dis; 2005 Jan; 64(1):160-2. PubMed ID: 15608321
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
    Konnopka A; Conrad K; Baerwald C; König HH
    Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
    Kitahara K; Takagi K; Kusunoki Y; Nishio S; Nozaki T; Inomata H; Takei M; Sawada S; Kawai S
    Ann Rheum Dis; 2008 Jul; 67(7):1059-60. PubMed ID: 18556455
    [No Abstract]   [Full Text] [Related]  

  • 18. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids.
    de Paz B; Alperi-López M; Ballina-García FJ; Prado C; Mozo L; Gutiérrez C; Suárez A
    J Rheumatol; 2010 Mar; 37(3):503-11. PubMed ID: 20080912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
    Feitsma AL; Toes RE; Begovich AB; Chokkalingam AP; de Vries RR; Huizinga TW; van der Helm-van Mil AH
    Rheumatology (Oxford); 2007 Jul; 46(7):1092-5. PubMed ID: 17341507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.